Skip to main content
Grafa
Health
Amgen reports Repatha 20% death risk reduction
Image for illustrative purposes only. Not a real photo.

Amgen reports Repatha 20% death risk reduction

Share
  • Amgen reported Phase 3 VESALIUS-CV data showing Repatha reduced the risk of death by 20% in more than 12,000 high-risk adults.
  • The trial showed lower cardiovascular mortality and fewer heart attacks when Repatha was added to existing LDL-C–lowering therapy.
  • Amgen said the results support the use of Repatha for broader cardiovascular risk reduction beyond patients with previous heart events.

Amgen (NASDAQ:AMGN) reported Phase 3 VESALIUS-CV trial results showing Repatha reduced the risk of death by 20% among more than 12,000 high-risk adults without previous heart attack or stroke over a median 4.6-year follow-up.

The findings expanded on earlier VESALIUS-CV results, which showed a 25% relative reduction in 3-point major adverse cardiovascular events and a 19% reduction in 4-point major adverse cardiovascular events.

The company reported that Repatha lowered overall mortality and cardiovascular mortality when added to statins or other LDL-C–lowering treatments, while reducing first, subsequent, and total cardiovascular events.

The trial also showed that Repatha reduced heart attack risk as early as six months, with participants achieving a median LDL-C level of 45 mg/dL compared with 109 mg/dL in the comparison group.

Amgen said the results support the potential use of Repatha in high-risk adults without prior cardiovascular events.

Amgen develops medicines across several therapeutic areas, including cardiovascular disease, oncology, inflammation, and rare diseases, with Repatha approved as an LDL-C–lowering therapy.

Repatha is a PCSK9 inhibitor designed to reduce LDL cholesterol levels, and the VESALIUS-CV study adds further clinical data on its impact on cardiovascular outcomes.

Frequently asked questions